Kenvue Inc

Kenvue Inc(KVUE)股票分析

$18.910

+0.244 (+1.29%)收盘时

Loading chart…
最高
18.945
开盘
18.740
成交量加权均价
18.86
成交量
27.69M
市值
35.27B
最低
18.715
成交额
522.22M
企业价值/息税折旧摊销前利润(TTM)
11.79

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

AI 分析 of Kenvue Inc (KVUE)

买入

Kenvue Inc is a good buy right now due to its current price of $17.7 being below the analyst price target of $19, indicating potential upside. Additionally, the forward P/E ratio of 14.73 suggests the stock is reasonably valued compared to its earnings potential. However, the main risk is the RSI at 55.20, which indicates it is approaching overbought territory, suggesting caution may be warranted in the short term.

分析师评级(1)

-0.26% 下跌空间
卖出
0 买入
0 持有
1 卖出
当前: 18.91
最低
17.00
平均
18.86
最高
23.00

UBS

2026-08-11

目标价

$19

中性

Barclays

2026-07-21

目标价

$19

Equal Weight

UBS

2026-07-16

目标价

$20

中性

Citi

2026-04-15

目标价

$19

中性

Barclays

2026-04-14

目标价

$18

Equal Weight

估值指标

Kenvue Inc(KVUE)当前预期市盈率为 14.73,5 年平均预期市盈率为 17.52。

预期市盈率

低估
5 年均值 P/E
17.52
当前P/E
14.73
高估
19.72
低估
15.32

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
12.65
当前EV/EBITDA
11.79
高估
13.79
低估
11.50

预期市销率

合理
5 年均值 P/S
2.48
当前P/S
2.25
高估
2.81
低估
2.15

Alphio AI 对 KVUE 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%KVUE

$25.34

情景价格

基

基准

基准 · 50%KVUE

$22.26

情景价格

悲

悲观

悲观 · 25%KVUE

$19.40

情景价格

持有 KVUE 的大户

I

Ingalls & Snyder, LLC

+ 持有KVUE

+9.84%

3个月收益率

M

Millennium Management LLC

+ 持有KVUE

+8.78%

3个月收益率

Y

Yacktman Asset Management LP

+ 持有KVUE

+7.03%

3个月收益率

T

Troy Asset Management Ltd

+ 持有KVUE

+6.32%

3个月收益率

B

Burgundy Asset Management Ltd.

+ 持有KVUE

+6.08%

3个月收益率

Y

Y-Intercept (Hong Kong) Limited

+ 持有KVUE

+5.48%

3个月收益率

KVUE 常见问题 —— 由 Alphio AI 解答

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). It operates in the Consumer Non-Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Kenvue Inc is a good buy right now due to its current price of $17.7 being below the analyst price target of $19, indicating potential upside. Additionally, the forward P/E ratio of 14.73 suggests the stock is reasonably valued compared to its earnings potential. However, the main risk is the RSI at 55.20, which indicates it is approaching overbought territory, suggesting caution may be warranted in the short term.

1 analysts cover KVUE: 0 rate it Buy, 0 Hold and 1 Sell. The average price target is 18.86.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易